Davis Stephen
CEO at ACAD; EVP & COO at INTRABIOTICS PHARMACEUTICALS INC /DE
- Sold, on record
- $33.4M
- Dollars the filings state
- Form 4 sales
- 34
- Latest Aug 19, 2024
- Form 144 notices
- 2
- Proposed sales
- Companies
- 2
- Filed as an executive or holder
Companies
- ACADACADIA PHARMACEUTICALS INCCEO
- INTRABIOTICS PHARMACEUTICALS INC /DEEVP & COO
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- ACAD901,217 shares
- INTRABIOTICS PHARMACEUTICALS INC /DE6,218 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale ACADUnusualJul 14, 2023 2023
Sold 100,000 shares at $30.04 ($3M)
Davis Stephen, CEO
10b5-1 planSold 73.2% of holdings ($4.1M position)36,695 shares left25.5x usual sizeFollows a Form 144Filing
- 2 Form 4 sale ACADUnusualOct 6, 2023 +84 days
Sold 51,563 shares at $21.96 ($1.1M)
Davis Stephen, CEO
No 10b5-1 planSold 36.6% of holdings ($3.1M position)89,131 shares left13.1x usual sizeFollows a Form 144Filing
- 3 Form 4 sale ACADNo planJan 8, 2024 +94 days
Sold 3,732 shares at $29.96 ($112k)
Davis Stephen, CEO
No 10b5-1 planSold 3.7% of holdings ($3M position)96,521 shares left0.6x usual sizeFiling
- 4 Form 4 sale ACADNo planFeb 26, 2024 +49 days
Sold 5,577 shares at $24.67 ($138k)
Davis Stephen, CEO
No 10b5-1 planSold 5.2% of holdings ($2.7M position)101,890 shares left0.8x usual sizeFiling
- 5 Form 4 sale ACADUnusualMar 27, 2024 +30 days
Sold 17,714 shares at $17.90 ($317k)
Davis Stephen, CEO
No 10b5-1 planSold 13% of holdings ($2.4M position)118,842 shares left3.2x usual sizeFiling
- 6 Form 4 sale ACADUnusualApr 8, 2024 +12 days
Sold 26,574 shares at $17.87 ($475k)
Davis Stephen, CEO
No 10b5-1 planSold 15.6% of holdings ($3.1M position)144,267 shares left4x usual sizeFiling
- 7 Form 4 sale ACADNo planMay 2, 2024 +24 days
Sold 11,427 shares at $16.94 ($194k)
Davis Stephen, CEO
No 10b5-1 planSold 6.9% of holdings ($2.8M position)155,231 shares left1.4x usual sizeFiling
- 8 Form 4 sale ACADUnusualAug 19, 2024 +109 days
Sold 31,747 shares at $15.28 ($485k)
Davis Stephen, CEO
No 10b5-1 planSold 14.5% of holdings ($3.3M position)186,555 shares left3.7x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (36)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Aug 19, 2024 | Aug 20, 2024 | ACAD | CEO | Form 4 sale | 31,747 | $485k | 14.5% | Unusual | SEC |
| May 2, 2024 | May 3, 2024 | ACAD | CEO | Form 4 sale | 11,427 | $194k | 6.9% | No plan | SEC |
| Apr 8, 2024 | Apr 9, 2024 | ACAD | CEO | Form 4 sale | 26,574 | $475k | 15.6% | Unusual | SEC |
| Mar 27, 2024 | Mar 27, 2024 | ACAD | CEO | Form 4 sale | 17,714 | $317k | 13.0% | Unusual | SEC |
| Feb 26, 2024 | Feb 27, 2024 | ACAD | CEO | Form 4 sale | 5,577 | $138k | 5.2% | No plan | SEC |
| Jan 8, 2024 | Jan 9, 2024 | ACAD | CEO | Form 4 sale | 3,732 | $112k | 3.7% | No plan | SEC |
| Oct 6, 2023 | Oct 6, 2023 | ACAD | CEO | Form 4 sale | 51,563 | $1.1M | 36.6% | Unusual | SEC |
| Jul 14, 2023 | Jul 18, 2023 | ACAD | CEO | Form 4 sale | 100,000 | $3M | 73.2% | Unusual | SEC |
| Jul 14, 2023 | Jul 14, 2023 | ACAD | Officer, Director | Form 144 notice | 100,000 | $2.6M | Notice | SEC | |
| Jul 13, 2023 | Jul 13, 2023 | ACAD | Officer, Director | Form 144 notice | 71,602 | $1.8M | Notice | SEC | |
| Jul 12, 2023 | Jul 13, 2023 | ACAD | CEO | Form 4 sale | 71,602 | $1.8M | 66.1% | Unusual | SEC |
| May 1, 2023 | May 2, 2023 | ACAD | CEO | Form 4 sale | 7,806 | $165k | 6.7% | No plan | SEC |
| Apr 6, 2023 | Apr 7, 2023 | ACAD | CEO | Form 4 sale | 8,582 | $156k | 7.9% | No plan | SEC |
| Feb 24, 2023 | Feb 27, 2023 | ACAD | CEO | Form 4 sale | 3,851 | $72k | 4.0% | Plan not stated | SEC |
| Jan 9, 2023 | Jan 10, 2023 | ACAD | CEO | Form 4 sale | 3,904 | $67k | 4.4% | Plan not stated | SEC |
| Oct 15, 2022 | Oct 18, 2022 | ACAD | CEO | Form 4 sale | 2,804 | $44k | 3.4% | Plan not stated | SEC |
| May 2, 2022 | May 3, 2022 | ACAD | CEO | Form 4 sale | 5,483 | $100k | 6.7% | Plan not stated | SEC |
| Feb 23, 2022 | Feb 25, 2022 | ACAD | CEO | Form 4 sale | 3,928 | $93k | 5.6% | Plan not stated | SEC |
| Jan 6, 2022 | Jan 10, 2022 | ACAD | CEO | Form 4 sale | 3,718 | $86k | 6.0% | Plan not stated | SEC |
| Oct 18, 2021 | Oct 19, 2021 | ACAD | CEO | Form 4 sale | 2,963 | $52k | 5.3% | Plan not stated | SEC |
| Apr 30, 2021 | Apr 30, 2021 | ACAD | CEO | Form 4 sale | 7,850 | $160k | 13.7% | Plan not stated | SEC |
| Feb 4, 2021 | Feb 8, 2021 | ACAD | CEO | Form 4 sale | 14,195 | $718k | 32.9% | Unusual | SEC |
| Jan 6, 2021 | Jan 8, 2021 | ACAD | CEO | Form 4 sale | 3,484 | $186k | 12.5% | Plan not stated | SEC |
| Oct 16, 2020 | Oct 19, 2020 | ACAD | CEO | Form 4 sale | 2,960 | $126k | 16.7% | Plan not stated | SEC |
| May 14, 2020 | May 15, 2020 | ACAD | CEO | Form 4 sale | 200,000 | $9.2M | 94.4% | Unusual | SEC |
| Apr 30, 2020 | May 1, 2020 | ACAD | CEO | Form 4 sale | 6,770 | $333k | 36.4% | Unusual | SEC |
| Dec 5, 2019 | Dec 6, 2019 | ACAD | CEO | Form 4 sale | 150,000 | $7.9M | 98.1% | Unusual | SEC |
| Oct 15, 2019 | Oct 17, 2019 | ACAD | CEO | Form 4 sale | 2,983 | $118k | 50.2% | Unusual | SEC |
| Oct 10, 2019 | Oct 11, 2019 | ACAD | CEO | Form 4 sale | 150,000 | $6M | 100.0% | Unusual | SEC |
| Jan 6, 2012 | Jan 6, 2012 | INTRABIOTICS PHARMACEUTICALS INC /DE | EVP & COO | Form 4 sale | 700 | $11k | 4.1% | Plan not stated | SEC |
| Nov 15, 2011 | Nov 17, 2011 | INTRABIOTICS PHARMACEUTICALS INC /DE | EVP & COO | Form 4 sale | 432 | $8k | 2.4% | Plan not stated | SEC |
| Oct 6, 2011 | Oct 7, 2011 | INTRABIOTICS PHARMACEUTICALS INC /DE | EVP & COO | Form 4 sale | 700 | $11k | 3.9% | Plan not stated | SEC |
| Jul 6, 2011 | Jul 8, 2011 | INTRABIOTICS PHARMACEUTICALS INC /DE | EVP & COO | Form 4 sale | 700 | $18k | 3.6% | Plan not stated | SEC |
| May 16, 2011 | May 18, 2011 | INTRABIOTICS PHARMACEUTICALS INC /DE | EVP & COO | Form 4 sale | 335 | $9k | 1.7% | Plan not stated | SEC |
| Apr 8, 2011 | Apr 8, 2011 | INTRABIOTICS PHARMACEUTICALS INC /DE | EVP & COO | Form 4 sale | 3,000 | $85k | 13.2% | Plan not stated | SEC |
| Nov 22, 2010 | Nov 22, 2010 | INTRABIOTICS PHARMACEUTICALS INC /DE | EVP & COO | Form 4 sale | 351 | $8k | 1.4% | Plan not stated | SEC |